window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date());gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 17, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

mHTT

  • Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    SKY-0515 shows 1.59-point cUHDRS difference in Huntington’s disease study

    Skyhawk Therapeutics’ investigational oral treatment SKY-0515 showed a 1.59-point difference [...]

    September 17, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Skyhawk expands global Huntington’s disease trial following positive Phase 1/2 data

    Skyhawk Therapeutics has expanded its global pivotal Phase 2/3 clinical [...]

    July 14, 2026
  • Advanced Therapies,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Skyhawk reports encouraging 12-month Huntington’s disease data for SKY-0515

    Skyhawk Therapeutics has reported encouraging 12-month results from its ongoing [...]

    June 6, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Researchers develop human iPS cell model of heart failure
    Categories: Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Resolution Therapeutics completes Phase 1/2 RTX001 liver disease trial dosing
    Categories: Advanced Therapies, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Eleva separates biologics platform from Factor H therapy
    Categories: Advanced Therapies, Biotech & Pharma Business, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top